Skip to main content

Alex

Analyst

Truist Securities

Equibles does not estimate personal net worth.

About Alex

Alex is recorded as Analyst at Truist Securities. Alex has spoken on 7 earnings calls across 7 companies, most recently for Altimmune, Inc. on November 12, 2026. Those appearances were for Altimmune, Inc. (ALT), Scholar Rock Holding Corp (SRRK), Cytokinetics Inc (CYTK), Wave Life Sciences, Inc. (WVE), Harmony Biosciences Holdings, Inc. (HRMY) and 2 other companies. The companies whose calls Alex spoke on are classified in the Healthcare sector.

Alex on recent calls

“Can you provide an update on how you're thinking about potential partnering or the lack thereof in order to optimize the development of PENVI across all three indications?”
Analyst — Truist, Q3 FY2026 Earnings conference call (announced in 8-K) ·
“For the 60 to 90 days from script to infusion, do you expect that that will continue up until you get the J code in April, or could that be trimmed down as more payers-established policies?”
Analyst — Truist Securities, Scholar Rock Q3 2026 Financial Results and Business Update Conference Call ·
“We wanted to know, ahead of the launches and the additional ex-U.S. markets next year, can you provide any color on the discussions that you've had with prescribers, and how would you classify the physician appetite for Mycorso versus how much additional physician education may be needed to drive growth in the market?”
Analyst — Truist Securities, Cytokinetics Q3 2026 Earnings Conference Call ·
“One follow-up on Jay's question on OnStride 1 and 2. Have those begun enrolling patients? Just we haven't seen any indication in clintrials.gov. And then on the OPEX expenditure, you mentioned the impact of some of the settlements and litigation.”
Analyst — Truist Securities, Harmony Biosciences Holdings, Inc. Q4 FY2025 Earnings Call ·

Affiliation history

  • Truist Securities

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity